Dofequidar fumarate

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameDofequidar fumarate

Drug Alias Namedofequidar富马酸多非喹达富马酸多非奎达dofequidarumMS-209

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionP-glycoprotein 1 inhibitors

TargetsP-glycoprotein 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBayer AG

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms

ATC CodeN/A